{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:51:54Z","timestamp":1789480314469,"version":"build-2803163510"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anoikis, a unique form of cell death, serves as a vital part of the organism's defense by preventing shedding cells from re-attaching to the incorrect positions, and plays pivotal role in cancer metastasis. Nonetheless, the specific mechanisms among anoikis, the clinical prognosis and tumor microenvironment (TME) of bladder cancer (BLCA) are insufficiently understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>BLCA patients were classified into different anoikis subtypes based on the expression of candidate anoikis-related genes (ARGs), and differences in the clinicopathological features, TME, immune cell infiltration, and immune checkpoints between two anoikis subtypes were analyzed. Next, patients in the TCGA cohort were randomized into the train and test groups in a 1:1 ratio. Subsequently, the anoikis-related model was constructed to predict the prognosis via utilizing the univariate Cox, LASSO and multivariate Cox analyses, and validated internally and externally. Moreover, the relationships between the risk score and clinicopathologic features, immune cell infiltration, immunotherapy response, and antitumor drug sensitivity were also analyzed. In addition, representative genes were evaluated using immunohistochemistry in clinical specimens, and in BLCA cell lines, functional experiments were performed to determine the biological behavior of hub gene PLOD1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>Two definite anoikis subgroups were identified. Compared to ARGcluster A, patients assigned to ARGcluster B were characterized by an immunosuppressive microenvironment and worse prognosis. Then, the anoikis-related model, including PLOD1, EHBP1, and CSPG4, was constructed, and BLCA patients in the low-risk group were characterized by a better prognosis. Next, the accurate nomogram was built to improve the clinical applicability by combining the age, tumor stage and risk Score. Moreover, immune infiltration and clinical features differed significantly between high- and low-risk groups. We also found that the low-risk group exhibited a lower tumor immune dysfunction and exclusion score, a higher immunophenoscore (IPS), had more sensitivity to immunotherapy. Eventually, the expression levels of three genes were verified by our experiment, and knockdown of PLOD1 could inhibit invasion and migration abilities in BLCA cell lines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results demonstrated a new direction in precision therapy for BLCA, and indicated that the ARGs might be helpful to in predicting prognosis and as therapeutic targets in BLCA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1491808","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T06:33:43Z","timestamp":1732689223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of anoikis-related molecular patterns and the novel risk model to predict prognosis, tumor microenvironment infiltration and immunotherapy response in bladder cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Luochen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11912-021-01091-1","article-title":"Approaches to non-muscle-invasive bladder cancer","volume":"23","author":"Slovacek","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e18384","DOI":"10.1111\/jcmm.v28.10","article-title":"Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target","volume":"28","author":"Wang","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcmm.18213","article-title":"Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target","volume":"28","author":"Wang","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S135157","article-title":"PD1\/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer","volume":"11","author":"Stenehjem","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e27184","DOI":"10.1016\/j.heliyon.2024.e27184","article-title":"Multidimensional pan-cancer analysis of HSPA5 and its validation in the prognostic value of bladder cancer","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.07.023","article-title":"Anoikis: a necessary death program for anchorage-dependent cells","volume":"76","author":"Chiarugi","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(97)80124-X","article-title":"Integrins and anoikis","volume":"9","author":"Frisch","year":"1997","journal-title":"Curr Opin Cell Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"306879","DOI":"10.1155\/2012\/306879","article-title":"Anoikis resistance: an essential prerequisite for tumor metastasis","volume":"2012","author":"Kim","year":"2012","journal-title":"Int J Cell Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626577","article-title":"Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming","volume":"11","author":"Adeshakin","year":"2021","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.v119.3","article-title":"Anoikis resistance and oncoviruses","volume":"119","author":"Kakavandi","year":"2018","journal-title":"J Cell Biochem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13046-022-02381-7","article-title":"CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells","volume":"41","author":"Yu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-021-00374-x","article-title":"HBXIP induces anoikis resistance by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis and stabilize Prdx1 in breast cancer","volume":"8","author":"Zhou","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2016.15","article-title":"Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells","volume":"23","author":"Mason","year":"2016","journal-title":"Cell Death Differ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.7150\/thno.51646","article-title":"The 14-3-3\u03c3 protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1\/2 signaling pathway","volume":"11","author":"Song","year":"2021","journal-title":"Theranostics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12079-021-00649-9","article-title":"BMP4 enhances anoikis resistance and chemoresistance of breast cancer cells through canonical BMP signaling","volume":"16","author":"Sharma","year":"2022","journal-title":"J Cell Commun Signal"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2008.178","article-title":"Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K\/Akt2","volume":"16","author":"Moro","year":"2009","journal-title":"Cell Death Differ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.17305\/bb.2024.9979","article-title":"JAM3: A prognostic biomarker for bladder cancer via epithelial-mesenchymal transition regulation","volume":"24","author":"Pang","year":"2024","journal-title":"Biomol BioMed"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3375297","DOI":"10.1155\/2021\/3375297","article-title":"Development of biomarker signatures associated with anoikis to predict prognosis in endometrial carcinoma patients","volume":"2021","author":"Chen","year":"2021","journal-title":"J Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055304","article-title":"Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking","volume":"26","author":"Wilkerson","year":"2010","journal-title":"Bioinformatics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204863","article-title":"Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity","volume":"15","author":"Wang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1472-6947-8-53","article-title":"Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers","volume":"8","author":"Vickers","year":"2008","journal-title":"BMC Med Inform Decis Mak"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.965100","article-title":"Prognosis and immune infiltration analysis of endoplasmic reticulum stress-related genes in bladder urothelial carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01853-y","article-title":"A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma","volume":"40","author":"Wu","year":"2021","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13062-024-00494-x","article-title":"Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches","volume":"19","author":"Wang","year":"2024","journal-title":"Biol Direct"},{"key":"B36","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/gb-2014-15-3-r47","article-title":"Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines","volume":"15","author":"Geeleher","year":"2014","journal-title":"Genome Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.08.043","article-title":"Clinical significance of SPARC in esophageal squamous cell carcinoma","volume":"492","author":"Chen","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective","volume":"19","author":"Teoh","year":"2022","journal-title":"Nat Rev Urol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"100264","DOI":"10.1016\/j.ctarc.2020.100264","article-title":"Survival after radical cystectomy: Progressive versus De novo muscle invasive bladder cancer","volume":"25","author":"Vlaming","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"B42","doi-asserted-by":"publisher","first-page":"122974","DOI":"10.1016\/j.lfs.2024.122974","article-title":"ARNTL2 facilitates bladder cancer progression through potentiating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner","volume":"355","author":"Wang","year":"2024","journal-title":"Life Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e2300661","DOI":"10.1200\/PO.23.00661","article-title":"Identification and validation of prognostic model for tumor microenvironment-associated genes in bladder cancer based on single-cell RNA sequencing data sets","volume":"8","author":"Safder","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12935-021-02096-3","article-title":"A novel signature constructed by ferroptosis-associated genes (FAGs) for the prediction of prognosis in bladder urothelial carcinoma (BLCA) and associated with immune infiltration","volume":"21","author":"Luan","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B45","doi-asserted-by":"publisher","first-page":"10732748221129451","DOI":"10.1177\/10732748221129451","article-title":"Prognostic role of DNA damage response genes mutations and their association with the sensitivity of olaparib in prostate cancer patients","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1038\/s41598-022-07070-1","article-title":"AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma","volume":"12","author":"Liu","year":"2022","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2020.07.003","article-title":"EMT, MET, plasticity, and tumor metastasis","volume":"30","author":"Bakir","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41580-020-00314-w","article-title":"Cellular senescence in ageing: from mechanisms to therapeutic opportunities","volume":"22","author":"Di Micco","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06164-0","article-title":"Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies","volume":"187","author":"Surette","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.984273","article-title":"A novel anoikis-related gene signature predicts prognosis in patients with head and neck squamous cell carcinoma and reveals immune infiltration","volume":"13","author":"Chi","year":"2022","journal-title":"Front Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.7150\/jca.51849","article-title":"Acidic extracellular pH induces autophagy to promote anoikis resistance of hepatocellular carcinoma cells via downregulation of miR-3663-3p","volume":"12","author":"Wang","year":"2021","journal-title":"J Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3390\/brainsci12101349","article-title":"A bioinformatics-based analysis of an anoikis-related gene signature predicts the prognosis of patients with low-grade gliomas","volume":"12","author":"Zhao","year":"2022","journal-title":"Brain Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S171855","article-title":"Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer","volume":"10","author":"Mao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2598","article-title":"Tumor purity as an underlying key factor in glioma","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-024-10178-7","article-title":"Survival mechanisms of circulating tumor cells and their implications for cancer treatment","volume":"43","author":"Zhou","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ng.89","article-title":"Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer","volume":"40","author":"Gudmundsson","year":"2008","journal-title":"Nat Genet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu019","article-title":"Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells","volume":"35","author":"Ghalali","year":"2014","journal-title":"Carcinogenesis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01911","article-title":"Chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types","volume":"8","author":"Ilieva","year":"2017","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0067","article-title":"CSPG4 is a potential therapeutic target in anaplastic thyroid","volume":"31","author":"Egan","year":"2021","journal-title":"Cancer Thyroid"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01635-y","article-title":"Hypoxia-induced PLOD1 overexpression contributes to the Malignant phenotype of glioblastoma via NF-\u03baB signaling","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S399875","article-title":"Comprehensive analysis of the expression, prognosis, and biological significance of PLOD family in bladder cancer","volume":"16","author":"Chen","year":"2023","journal-title":"Int J Gen Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","article-title":"Role of immunotherapy in bladder cancer Cancer","volume":"26","author":"Rhea","year":"2021","journal-title":"Treat Res Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953761","article-title":"Safety and efficacy of programmed cell death 1 and programmed death ligand-1 inhibitors in the treatment of cancer: an overview of systematic reviews","volume":"13","author":"Ou","year":"2022","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v111.6","article-title":"CD20(+) tumor-infiltrating immune cells and CD204(+) M2 macrophages are associated with prognosis in thymic carcinoma","volume":"111","author":"Sato","year":"2020","journal-title":"Cancer Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.08.004","article-title":"The immune landscape of cancer","volume":"51","author":"Thorsson","year":"2019","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.935056","article-title":"Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1491808\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T06:33:53Z","timestamp":1732689233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1491808\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2024.1491808"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1491808","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"article-number":"1491808"}}